ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis

Thrombosis Research

Volumn 111, Issue 1-2, 2003, Pages 33-37

  Böhm, Martina ^a   Gerlach, Rüdiger ^a   Beecken, Wolf Dietrich ^a   Scheuer, Timm ^a   Stier Brück, Ingrid ^a   Scharrer, Inge ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

ADAMTS 13; Brain neoplasm; Prostate tumors; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR;

AGE DISTRIBUTION; ARTICLE; BRAIN TUMOR; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROENCEPHALOGRAM; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE TUMOR; SEX RATIO;

EID: 0345303929     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.08.018     Document Type: Article

References (22)

1. Xie L., Chesterman C.N., Hogg P.J. Control of von Willebrand factor multimer size by thrombospondin-1. J. Exp. Med. 193:2001;1341-1349.
2. Furlan M., Robles R., Lämmle B. Partial purification and characterisation of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 10:1996;4223-4234.
3. Tsai H.M. Physiologic cleavage of von Willebrand Factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 10:1996;4235-4244.
4. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 98:2001;1662-1666.
5. Gerritsen H.E., Robles R., Lämmle B., Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 98:2001;1654-1661.
6. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413:2001;488-494.
7. Schneppenheim R., Budde U., Oyen F., Angerhaus D., Aumann V., Drewke E., et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 101:2003;1845-1850.
8. Kokame K., Matsumoto M., Soejima K., Yagi H., Ishizashi H., Funato M., et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. PNAS. 99:2002;11902-11907.
9. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., et al. Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the Hemolytic-Uremic Syndrome. N. Engl. J. Med. 339:1998;1578-1584.
10. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339:1998;1585-1594.
11. Allford S.L., Harrison P., Lawrie A.S., Liesner R., Mackie I.J., Machin S.J. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br. J. Haematol. 111:2000;1215-1222.
12. Veyradier A., Obert B., Houllier A., Meyer D., Girma J.P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 98:2001;1765-1772.
13. Böhm M., Vigh T., Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann. Hematol. 81:2002;430-435.
14. Oleksowicz L., Bhagwati N., DeLeon-Fernandez M. Deficient activity of von Willebrand's factor cleaving protease in patients with disseminated malignancies. Cancer Res. 59:1999;2244-2250.
15. Koo B.H., Oh D., Chung S.Y., Kim N.K., Park S., Jang Y., et al. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb. Res. 105:2002;471-476.
16. Fontana S., Gerritsen H.E., Kremer Hovinga J., Furlan M., Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br. J. Haematol. 113:2001;100-102.
17. Mannucci P.M., Karimi M., Mosalaei A., Canciani M.T., Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica. 88:2003;454-458.
18. Studt J.D., Böhm M., Budde U., Girma J.P., Varadi K., Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J. Thromb. Haemost. 1:2003;1882-1887.
19. Mannucci P.M., Canciani M.T., Forza I., Lussana F., Lattuada A., Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 98:2001;2730-2735.
20. Bianchi V., Robles R., Alberio L., Furlan M., Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 100:2002;710-713.
21. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276:2001;41059-41063.
22. Park Y.D., Yoshioka A., Kawa K., Ishizashi H., Yagi H., Yamamoto Y., et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant. 29:2002;789-794.